VRTX Vertex PharmaceuticalscompanySEC Filings & Insider Trading Activity 2026
Latest Vertex Pharmaceuticals (VRTX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 13, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Vertex Pharmaceuticals (VRTX) (SEC CIK 875320), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Management Discussion & Analysis
- • Revenue $12.0B in 2025, up 9% YoY from $11.0B in 2024; TRIKAFTA/KAFTRIO sales $10.3B (1% increase), ALYFTREK $837.8M launched in 2025
- • Operating margin approx. 34.7% in 2025 vs 13.8% cost of sales (13.8% of net product revenues), slight improvement from 13.9% in 2024; R&D + SG&A expenses $5.7B up from $5.1B
Business Overview
- • Core business model: Biopharmaceutical company focused on developing and commercializing transformative medicines
- • Emphasis on enhanced cybersecurity governance with dedicated CISO and quarterly Board updates
Risk Factors
- • Regulatory risk: Impact of Colorado PDAB affordability review on TRIKAFTA pricing with potential upper payment limits under the 2023 state program
- • Macroeconomic risk: Ex-U.S. reimbursement delays and government cost-containment efforts impacting pricing and revenue in various international markets
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $3.1B in Q3 2025, up 11% from $2.8B in Q3 2024, driven by TRIKAFTA/KAFTRIO and new launches including ALYFTREK and JOURNAVX
- • Operating margin improved: income from operations $1.19B (39% margin) in Q3 2025 vs $1.12B (40% margin) in Q3 2024, cost of sales down to 13.5% from 14.2%
Risk Factors
- • No newly added risk factors this quarter; no material changes from 2024 10-K risk disclosures
- • Carryforward regulatory risk: challenges obtaining accelerated approvals and maintaining reimbursement coverage
Annual Reports Archive10-K
AI-powered analysis of Vertex Pharmaceuticals (VRTX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Vertex Pharmaceuticals (VRTX) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $8.9B | $9.9B | $11.0B | $12.0B |
| Operating Income | $4.3B | $3.8B | -$232.9M | $4.2B |
| Net Income | $3.3B | $3.6B | -$535.6M | $4.0B |
| Op. Margin | 48.2% | 38.8% | -2.1% | 34.8% |
| Net Margin | 37.2% | 36.7% | -4.9% | 32.9% |
| Balance Sheet | ||||
| Total Assets | $18.2B | $22.7B | $22.5B | $25.6B |
| Equity | $13.9B | $17.6B | $16.4B | $18.7B |
| ROE | 23.9% | 20.6% | -3.3% | 21.2% |
Source: XBRL financial data from Vertex Pharmaceuticals (VRTX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 29, 2026 | — | — | — |
8-K | Mar 31, 2026 | — | — | — |
10-K | Feb 13, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | Analysis | |
10-Q | May 6, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 13, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 5, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 2, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 15, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 2, 2023 | Mar 31, 2023 | — | |
10-K | Feb 10, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 28, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 9, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 30, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 30, 2021 | Mar 31, 2021 | — | |
10-K | Feb 11, 2021 | Dec 31, 2020 | — | |
10-Q | Oct 30, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest VRTX SEC filings in 2026?
Vertex Pharmaceuticals (VRTX) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did VRTX file its most recent 10-K annual report?
Vertex Pharmaceuticals (VRTX) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view VRTX 10-Q quarterly reports?
Vertex Pharmaceuticals (VRTX)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every VRTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has VRTX filed recently?
Vertex Pharmaceuticals (VRTX)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find VRTX insider trading activity (Form 4)?
SignalX aggregates every VRTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does VRTX file with the SEC?
Vertex Pharmaceuticals (VRTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VRTX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vertex Pharmaceuticals (VRTX).
What is VRTX's SEC CIK number?
Vertex Pharmaceuticals (VRTX)'s SEC CIK (Central Index Key) number is 875320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 875320 to look up all VRTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find VRTX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Vertex Pharmaceuticals (VRTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Vertex Pharmaceuticals SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 28+ filings.